Yap P L
Edinburgh and South East Scotland Blood Transfusion Service, UK.
Malays J Pathol. 1990 Jun;12(1):1-10.
Intravenous immunoglobulin (IV Ig) preparations allow large amounts of IgG to be administered rapidly and painlessly. Currently, there are a number of IV IgG preparations available which differ in their manufacturing methods. However, all the licensed preparations are associated with a low incidence of adverse reactions on administration. They are used mainly for IgG replacement therapy in patients suffering from primary hypogammaglobulinaemia and other patients with antibody deficiency suffering from recurrent infections. A few patients with secondary hypogammaglobulinaemia and recurrent infections also benefit from IV IgG therapy, particularly patients with haematological malignancies. IV IgG in high dosage (greater than 100 g per patient) is also useful for non-immunodeficient conditions such as idiopathic thrombocytopenic purpura but widespread use in this condition is limited by the relatively short duration of IV IgG action in autoimmune disease, and by the cost of high dose IV IgG therapy.
静脉注射免疫球蛋白(IV Ig)制剂可快速且无痛地给予大量IgG。目前,有多种IV IgG制剂,其制造方法各不相同。然而,所有已获许可的制剂在给药时不良反应发生率都很低。它们主要用于原发性低丙种球蛋白血症患者及其他患有抗体缺乏且反复感染的患者的IgG替代治疗。一些继发性低丙种球蛋白血症且反复感染的患者也可从IV IgG治疗中获益,尤其是血液系统恶性肿瘤患者。高剂量(每位患者大于100 g)的IV IgG对特发性血小板减少性紫癜等非免疫缺陷性疾病也有用,但在这种情况下的广泛应用受到IV IgG在自身免疫性疾病中作用持续时间相对较短以及高剂量IV IgG治疗费用的限制。